308 Spam-Free Article(s) Found
Sort:
Relevance
Like
Date
Filter:
7d
All
DeepLinks
Article Searches
Wall Street Analysts See CVS Health (CVS) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2238562/wall-street-analysts-see-cvs-health-cvs-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2238562 Mar 11, 2024 - According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2239298/wall-street-analysts-see-a-31-41-upside-in-y-mabs-therapeutics-inc-ymab-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2239298 Mar 12, 2024 - The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 29.76% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2239992/wall-street-analysts-see-a-29-76-upside-in-tactile-systems-technology-tcmd-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2239992 Mar 13, 2024 - The mean of analysts' price targets for Tactile Systems Technology (TCMD) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See Meta Platforms (META) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2241325/wall-street-analysts-see-meta-platforms-meta-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2241325 Mar 15, 2024 - Based on the average brokerage recommendation (ABR), Meta Platforms (META) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2242073/wall-street-analysts-see-adma-biologics-adma-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2242073 Mar 18, 2024 - The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2242201/wall-street-analysts-see-a-54-78-upside-in-arcutis-biotherapeutics-inc-arqt-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2242201 Mar 18, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See Synopsys (SNPS) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2243349/wall-street-analysts-see-synopsys-snps-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2243349 Mar 20, 2024 - According to the average brokerage recommendation (ABR), one should invest in Synopsys (SNPS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Wall Street Analysts See a 33.98% Upside in Zuora (ZUO): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2245518/wall-street-analysts-see-a-33-98-upside-in-zuora-zuo-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2245518 Mar 25, 2024 - The mean of analysts' price targets for Zuora (ZUO) points to a 34% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Delta Air Lines (DAL) Sees a More Significant Dip Than Broader Market: Some Facts to Know https://www.zacks.com/stock/news/2245666/delta-air-lines-dal-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2245666 Mar 25, 2024 - Delta Air Lines (DAL) reachead $45.42 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.
Wall Street Analysts See Danaher (DHR) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2246601/wall-street-analysts-see-danaher-dhr-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2246601 Mar 27, 2024 - According to the average brokerage recommendation (ABR), one should invest in Danaher (DHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Pages: 1...2425262728293031

<<<Page 29>